Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Inclusion Criteria: * Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX and FOLFIRI. * Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF V600E mutation may be enrolled regardless of prior chemotherapy. * Exception: Patients whose tumors are MSI-H must have experience progression through immunotherapy in addition to the therapies mentioned above. * Patients with metastatic pancreatic adenocarcinoma. * Patients with metastatic gastric or esophageal cancer whose tumor has progressed through first-line chemotherapy of any type. * Patients with metastatic cholangiocarcinoma whose tumor has progressed through first-line chemotherapy of any type. * Patients with metastatic hepatocellular carcinoma whose tumor has progressed through PD1 blockade. * Patients with metastatic high-grade neuroendocrine tumor. * A patient with a metastatic GIST that has progressed through first-line tyrosine kinase inhibitor. * Expected life expectancy of at least one month Exclusion Criteria: * Any patient not meeting the above criteria * Non-English speaking patients